P0721: Anti-TNFs have similar safety profile to vedolizumab and ustekinumab as first line biologic treatment in elderly patients with Crohn’s diseaseECCO'25Year: 2025
Authors: Thurm, T.(1)*;Javits, L.(2);Nachmias, N.(3);Cohen, N.A.(1);Leibovitzh, H.(1);Hirsch, A.(1);Ron, Y.(1);Maharshak, N.(1);
(1)Tel Aviv Sourasky Medical Center- affiliated with the Faculty of Medical and Health Sciences- Tel Aviv University, IBD center- Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(2)Tel Aviv University, Faculty of Medical and Health Sciences, Tel Aviv, Israel;(3)Tel Aviv Sourasky Medical Center- affiliated with Faculty of Medical and Health Sciences- Tel Aviv University, Internal Medicine Department D, Tel Aviv, Israel;
P0722: Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease: Results From the One-Year SEQUENCE Open-Label Long-Term ExtensionECCO'25Year: 2025
Authors: Peyrin-Biroulet, L.(1)*;Atreya , R.(2);Danese, S.(3);Lindsay , J.O.(4);Chapman, J.C.(5);Anschutz, T.(6);Huang, X.(7);Zambrano, J.(8);Platt, A.(9);Joshi , N.(10);Cross , R.K.(11);
(1)Centre Hospitalier Régional Universitaire de Nancy, Department of Gastroenterology- INFINY Institute- INSERM NGERE, Vandœuvre-lès-Nancy, France;(2)Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany;(3)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(4)Queen Mary University of London, Centre for Immunobiology- Barts and the London School of Medicine and Dentistry, London, United Kingdom;(5)Baton Rouge General and the GI Alliance, Crohn's and Colitis Center, Baton Rouge, United States;(6)AbbVie, Clinical Development, North Chicago, United States;(7)AbbVie, Statistics, North Chicago, United States;(8)AbbVie, US Medical Affairs, North Chicago, United States;(9)AbbVie, International Medical Affairs, North Chicago, United States;(10)AbbVie, HEOR Strategy, North Chicago, United States;(11)Mercy Medical Center, Melissa L. Posner Institute for Digestive Health & Liver Disease, Baltimore, United States;
1. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. N Engl J Med. 2024 Jul 18;391(3):213–23.
2. Papp KA, de Vente S, Zeng J, Flack M, Padilla B, Tyring SK. Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial. Dermatol Ther (Heidelb). 2021 Apr;11(2):487–97.
3. Ferrante M, Panaccione R, Colombel JF, Dubinsky M, Hisamatsu T, Lindsay JO, et al. DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn’s Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension. Journal of Crohn’s and Colitis. 2024 Jan 24;18(Supplement_1):i168–70.
P0723: Lengthening ustekinumab treatment intervals from every 8 to every 12 weeks in IBD patients in stable remission: preliminary results of a prospective observational cohort studyECCO'25Year: 2025
Authors: Devillers, M.(1)*;Fons, A.(2);West, R.(3);Van Der Marel, S.(4);Theeuwen, R.(2);Van Schaik, F.(5);Löwenberg, M.(6);Visschedijk, M.(7);Pierik, M.(8);Mujagic, Z.(8);Duijvestein, M.(9);Lauranne, D.(1);De Vries, A.(1);Van Der Meulen-de Jong, A.(2);
(1)Erasmus MC University Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(2)Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;(3)Franciscus Gasthuis & Vlietland, Gastroenterology and hepatology, Rotterdam, The Netherlands;(4)Haaglanden Medisch Centrum, Gastroenterology and hepatology, The Hague, The Netherlands;(5)University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(6)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(8)Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands;(9)Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands; Initiative on Crohn’s and Colitis (ICC)
1.Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med 2016 Nov 17;375(20):1946-1960
2.Sands BE, Sandborn WJ, Pannaccione R, O’Brien CD, Zhang H, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2019 Sept 26; 381(13):1201-1214
3.Bai Y, Sun Y, He Q, Bai X, Yang H. Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2024 Apr 1;36(4):359-370
4.Straatmijer T, Biemans VBC, Hoentjen F, de Boer NKH, Bodelier AGL, Dijkstra G, et al. Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis 2021 Nov 8;15(11):1920-1930.
P0724: Endoscopic and radiological outcomes of strictureplasty in patients with small bowel stricturing Crohn's diseaseECCO'25Year: 2025
Authors: Zhang, X.(1)*;Li, Y.(2);Zhu, W.(3);
(1)Jinling Hospital- Medical School of Southeast University, Department of General Surgery, Nanjing, China;(2)Jinling Hospital, Department of General Surgery, Nanjing, China;(3)Affiliated Hospital of Nanjing University of Chinese Medicine, Department of Colorectal and Proctology, Nanjing, China;
P0725: The fragility of randomized clinical trials in evaluating novel therapies for Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Chen, R.(1)*;Zheng, J.(1);Huang, P.(2);Li, L.(1);Chen, M.(1);Zhang, S.(1);
(1)The First Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(2)Sun Yat-sen University, Zhongshan School of Medicine, Guangzhou, China;
1. Walsh M, Srinathan SK, McAuley DF, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol 2014;67:622-8.
2. Caldwell JE, Youssefzadeh K, Limpisvasti O. A method for calculating the fragility index of continuous outcomes. J Clin Epidemiol 2021;136:20-25.
P0726: The Moderating Role of Adverse Childhood Experiences in the Relationship between Crohn's Disease Activity and the Development of PTSD SymptomsECCO'25Year: 2025
Authors: Di Vincenzo, F.(1)*;Spagnolo, G.(2);Vecchione, M.(3);D'Onofrio, A.M.(4);Camardese, G.(4);Sani, G.(4);Gasbarrini, A.(5);Cammarota, G.(6);Chieffo, D.P.R.(2);Ferrarese, D.(2);Scaldaferri, F.(7);
(1)Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy;(2)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, Clinical Psychology Unit, Roma, Italy;(3)Sapienza University of Rome, Department of Social and Developmental Psychology, Roma, Italy;(4)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, Department of Neuroscience- Section of Psychiatry, Roma, Italy;(5)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, UOC Medicina Interna e Gastroenterologia- Digestive Disease Center CeMAD- Dipartimento di Scienze Mediche e Chirurgiche- Dipartimento di Medicina e Chirurgia Traslazionale, Roma, Italy;(6)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, UOC Gastroenterologia - Dipartimento di Scienze Mediche e Chirurgiche, Roma, Italy;(7)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, IBD Unit- CeMAD Translational Research Laboratories- Digestive Disease Center CeMAD- Dipartimento di Scienze Mediche e Chirurgiche- Dipartimento di Medicina e Chirurgia Traslazionale, Rome, Italy;
P0728: Interventions for ocular extraintestinal manifestations in inflammatory bowel disease: an umbrella review of systematic reviewsECCO'25Year: 2025
Authors: Estevinho, M.M.(1)*;Solitano, V.(2);Magro, F.(3);Yuan, Y.(2);Jairath, V.(2);
(1)Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de Gaia, Portugal;(2)Western University- London- Ontario, Gastroenterology, London, Canada;(3)Unidade Local de Saúde de São João, Gastroenterology, Porto, Portugal;
Licona Vera E, Betancur Vasquez C, Peinado Acevedo JS, Rivera Bustamante T, Martinez Redondo JM. Ocular Manifestations of Inflammatory Bowel Disease. Cureus. 2023;15(6):e40299
P0729: Comparative clinical outcomes of advanced therapy in bio-naïve versus bio-experienced patients hospitalized with Acute Severe Ulcerative Colitis: A retrospective cohort studyECCO'25Year: 2025
Authors: Hwang, S.W.(1,2)*;Kim, S.(1);Lee, C.H.(1);Kim, J.W.(1);Kim, M.K.(1);Lee, S.(1);Hong, S.W.(1);Park, S.H.(1,2);Yang, D.H.(1);Ye, B.D.(1,2);Byeon, J.S.(1);Myung, S.J.(1);Yang, S.K.(1,2);
(1)University of Ulsan College of Medicine- Asan Medical Center, Department of Gastroenterology and Internal Medicine, Seoul, Korea- Republic Of;(2)University of Ulsan College of Medicine- Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;
P0730: Inflammatory Bowel Disease Lifestyle Food and Exercise (IBDLiFE) study: a randomized controlled trial to investigate the effectiveness of a personalised diet and physical activity intervention for adults with inactive IBD in Aotearoa, New ZealandECCO'25Year: 2025
Authors: Yap, J.(1)*;Wall, C.L.(2);Meredith-Jones, K.(1);Iosua, E.(3);Osborne, H.(1);Michael, S.(1);
(1)University of Otago, Medicine, North Dunedin, New Zealand;(2)University of Otago, Medicine, Christchurch, New Zealand;(3)University of Otago, Biostatistics Centre, North Dunedin, New Zealand;
P0732: A cost comparison of treatment sequencing for Ulcerative Colitis: vedolizumab vs ustekinumab as a second-line biologic in anti-TNF-exposed patients in CanadaECCO'25Year: 2025
Authors: Martin, M.(1);Zhou, J.Y.(2)*;Mac, S.(2);Kao, K.E.(1);Johnston, K.(1);Marshall, J.K.(3);
(1)Broadstreet Health Economics and Outcomes Research, Broadstreet Health Economics and Outcomes Research, Vancouver, Canada;(2)Takeda Canada Inc., Patient Value and Access, Toronto, Canada;(3)McMaster University, Department of Medicine Division of Gastroenterology and Farncombe Family Digestive Health Research Institute-, Hamilton, Canada;
1. Wetwittayakhlang P, Lontai L, Gonczi L, et al. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med. 2021;10(23).
2. Bressler B. Is there an optimal sequence of biologic therapies for inflammatory bowel disease? Therap Adv Gastroenterol. 2023;16:17562848231159452.
P0733: REALASA: Real-world effectiveness assessment of first-line 5-ASA for the treatment of Ulcerative Colitis in SwedenECCO'25Year: 2025
Authors: Christophersen, B.(1);Nielsen, L.(2);Landeira, M.(3);Guedes, S.(4)*;
(1)Ferring Pharmaceuticals Inc., Medical Affairs, Copenhagen, Denmark;(2)Ferring Pharmaceuticals Inc., Statistics, Copenhagen, Denmark;(3)Ferring Pharmaceuticals Inc., Health Economics and Outcomes Research, Copenhagen, Denmark;(4)Ferring Pharmaceuticals Inc., Real-world Evidence, Copenhagen, Denmark;
P0734: Real-World Experience of Curcumin+Qing Dai Reduces Biochemical and Intestinal Ultrasound Disease Markers in Patients with Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Krugliak Cleveland, N.(1)*;Duty, C.(1);Bhondwe, K.(1);Rubin, D.(1);
(1)University of Chicago Medical Center, Inflammatory Bowel Disease Center, Chicago, United States;
1. Ben-Horin S, Salomon N, Karampekos G, et al. Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2024;22(2):347-356.e6. doi:10.1016/j.cgh.2023.05.023
P0735: Early dietetic assessment predicts clinical efficacy of Exclusive Enteral Nutrition in adults with Crohn’s diseaseECCO'25Year: 2025
Authors: Chu, M.(1,2,3)*;Day, A.S.(1,3,4);Bogatic, D.(1,2,3);Hatzi, M.(4);Chu, S.K.(2);Costello, S.P.(1,2,3);Bryant, R.V.(1,2,3);
(1)The Queen Elizabeth Hospital, The Department of Gastroenterology and Hepatology, Adelaide, Australia;(2)University of Adelaide, School of Health and Medical Sciences, Adelaide, Australia;(3)Basil Hetzel Institute, Inflammatory Bowel Disease Research Group, Adelaide, Australia;(4)The Queen Elizabeth Hospital, Nutrition and Dietetics, Adelaide, Australia;
P0736: Analysis of endoscopic recurrence risk factors in Crohn's disease after surgical treatment within 1 yearECCO'25Year: 2025
Authors: Wei, T.(1);Guo, H.(1)*;Xiaomei, S.(1);Le, H.(1);
(1)Chongqing General Hospital, Gastroenterology, Chongqing, China;
1. Katz S. "Mind the gap": an unmet need for new therapy in IBD. J Clin Gastroenterol. 2007;41(9):799-809. doi:10.1097/ MCG.0b013e318033d71d
2. Kayal M, Posner H, Spencer E, Colombel JF, Stalgis C, Ungaro RC. Net remission rates with biologic and small molecule treatment in ulcerative colitis: a reappraisal of the clinical trial data. Clin Gastroenterol Hepatol. Published online January 12, 2023. doi:10.1016/j.cgh.2023.01.005
3. TASNEEM A, FLORIAN R, CLAUDIO F, et al. Pathogenesis of postoperative recurrence in Crohn's disease.[J]. Gut, 2011,60(4)
4. SOLBERG I C, CVANCAROVA M, VATN M H, et al. Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn’s disease (the IBSEN Study)[J]. Inffamm Bowel Dis, 2014, 20(1): 60-68.
5. REGUEIRO M, KIP K E, BAIDOO L, et al. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence[J]. Clin Gastroenterol Hepatol, 2014, 12(9): 1494-1502.
6. Donnellan CF, Yann LH, Lal S. Nutritional management of Crohn’s disease. Therap Adv Gastroenterol. (2013) 6:231–42. doi: 10.1177/1756283X13477715
7. Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol. (2009) 15:2570–8. doi: 10.3748/wjg.15.2570
8. Van Assche G, Dignass A, Panes J, et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis 2010;4(1):7-27
9.朱维铭，李 毅，余 超，等． 肠部分切除后吻合方式对克罗 恩病术后复发的影响． 中华胃肠外科杂志，2011，14( 3) : 168- 170．
10.Kullberg J, Brandberg J, Angelhed J E, et al. Whole-body adipose tissue analysis: Comparison of MRI, CT and dual energy X-ray absorptiometry[J]. Br J Radiol, 2009,82(974):123-130.
P0738: Apulian Network for Inflammatory Bowel Disease (AN-IBD) safety profile: Pilot dataECCO'25Year: 2025
Authors: Ditonno , I.(1);Contaldo , A.(1)*;Dell'Aquila , P.(1);Suriano , V.(1);Bossa , F.(2);Annese , M.(2);Perri , F.(2);Mazzuoli , S.(3);Guglielmi , F.W.(3);Bringiotti , R.(4);Palmisano , C.M.(5);Pranzo , G.(5);Albano , F.(6);Neve , V.(6);Tonti , P.(6);Stasi , E.(7);Facciorusso , A.(7);Marzo , M.(8);Paiano , P.(8);Gatti , F.(9);Di Lorenzo , M.P.(9);Fanigliulo , L.(10);Panarese , A.(10);Allegretta , L.(11);Bucci , A.(12);Hadad , Y.(13);Pisani , A.(14);Sacco , R.(15);Tursi , A.(16);Principi , M.(1);
(1)Policlinico di Bari- University of Bari "Aldo Moro", Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J- Gastroenterology Unit, Bari, Italy;(2)“Fondazione IRCCS - Casa Sollievo della Sofferenza”, Division of Gastroenterology, San Giovanni Rotondo, Italy;(3)"Monsignor Raffaele Dimiccoli" Hospital, IBD Unit- U.O.C. of Gastroenterology, Barletta, Italy;(4)“Di Venere” Hospital, Digestive Endoscopy Unit, Bari, Italy;(5)"Valle D'Itria" Hospital, Ambulatory for IBD Treatment, Martina Franca, Italy;(6)"A. Perrino" Hospital, Division of Gastroenterology, Brindisi, Italy;(7)"Vito Fazzi" Hospital, Department of Gastroenterology and Digestive Endoscopy, Lecce, Italy;(8)"Veris-Delli Ponti" Hospital, Division of Gastroenterology, Scorrano, Italy;(9)“F. Perinei” Hospital, Division of Gastroenterology, Altamura, Italy;(10)"S.S. Annunziata" Hospital, Division of Gastroenterology, Taranto, Italy;(11)"Santa Caterina Novella" Hospital, Division of Gastroenterology, Galatina, Italy;(12)“San Paolo” Hospital, Division of Gastroenterology, Bari, Italy;(13)“Card. Panico” Hospital, Division of Internal Medicine, Tricase, Italy;(14)National Institute of Gastroenterology IRCCS "Saverio de Bellis", Gastroenterology Unit, Castellana Grotte, Italy;(15)"Ospedali Riuniti", Gastroenterology Unit, Foggia, Italy;(16)Territorial Gastroenterology Service, Asl BAT, Andria, Italy;
P0739: Treatment persistence, clinical, and biological outcomes following an elective switch from intravenous to subcutaneous infliximab and vedolizumabECCO'25Year: 2025
Authors: Outtier, A.(1)*;Hoffert, Y.(2);De Dycker, E.(1);Geens, P.(1);Lambrechts, T.(1);Loddewijkx, E.(1);Paps, A.(1);Verstockt, B.(1);Sabino, J.(1);Vermeire, S.(1);Ferrante, M.(1);
(1)UZ Leuven, Gastroenterology, Leuven, Belgium;(2)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium; TARGID
P0740: Effectiveness and safety of ustekinumab in elderly Crohn's Disease patientsECCO'25Year: 2025
Authors: Ruiz Núñez , I.(1);Morera Sauca , L.(1);Madrigal Domínguez , R.E.(2);Barrio Andrés , J.(1)*;De Prado Santos , Á.(1);Mata Román , L.(3);Marinero Muñoz , M.Á.(1);García Alonso , J.(1);
(1)Río Hortega Universitary Hospital, Gastrointestinal, Valladolid, Spain;(2)Valladolid Clinic Universitary Hospital, Gastrointestinal, Valladolid, Spain;(3)Medina Del Campo Hospital, Gastrointestinal, Medina Del Campo, Spain;
P0741: Adherence to mesalazine suppositories maintenance treatment in patients with ulcerative proctitis: MESUPO multicenter prospective observational study from GETECCUECCO'25Year: 2025
Authors: Ferreiro Iglesias, R.(1)*;Nieto García, L.(1);de Castro, M.L.(2);Pérez Galindo, P.(3);Hernández Camba, A.(4);García, M.J.(5);Calvo Íñiguez, M.(6);Rodríguez-Lago, I.(7);Martí, E.(8);Iriarte, A.(9);Pallarés, H.(10);Dueñas Sadornil, C.(11);Zabalza San Martín, L.(12);Ramirez de la Piscina, P.(13);Rodríguez, L.(14);Bastón Rey, I.(1);Martínez Cadilla, J.(2);Álvarez Cancelo, A.(15);Porto Silva, S.(1);Zabana, Y.(16);Barreiro-de Acosta, M.(1);
(1)Hospital Clínico Universitario de Santiago de Compostela. Fundación Instituto de Investigación Sanitaria de Santiago de Compostela FIDIS, Gastroenterology, Santiago de Compostela, Spain;(2)Complexo Hospitalario Universitario de Vigo CHUVI Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS-UVIGO, Gastroenterology, Vigo, Spain;(3)Complejo Hospitalario Universitario de Pontevedra. Instituto de Investigación Sanitaria Galicia Sur, Gastroenterology, Pontevedra, Spain;(4)Complejo Hospitalario Universitario Nuestra Señora de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(5)Hospital Universitario Marqués de Valdecilla. Grupo de Investigación Sanitaria Valdecilla IDIVAL. Universidad de Cantabria., Gastroenterology and Hepatology, Santander, Spain;(6)Hospital Universitario San Pedro-Logroño, Gastroenterology, Logroño, Spain;(7)Hospital Universitario de Galdakao- Biobizkaia Health Research Institute- Galdakao, Gastroenterology, Bilbao, Spain;(8)Hospital Universitario Lucus Augusti, Gastroenterology, Lugo, Spain;(9)Hospital Zumarraga- OSI Goierri-Alto Urola, Gastroenterology, Gipuzkoa, Spain;(10)Hospital Juan Ramón Jiménez, Gastroenterology, Huelva, Spain;(11)Hospital Universitario de Cáceres, Gastroenterology, Cáceres, Spain;(12)Hospital Universitario de Navarra. Instituto de Investigación de Navarra idiSNA, Gastroenterology, Navarra, Spain;(13)Hospital Universitario de Álava, Gastroenterology Department, Álava, Spain;(14)Hospital Universitario de Bellvitge, Gastroenterology, L’Hospitalet del Llobregat, Spain;(15)Hospital Universitario Marqués de Valdecilla. Grupo de Investigación Sanitaria Valdecilla IDIVAL, Gastroenterology and Hepatology, Santander, Spain;(16)CIBERhed. Hospital Universitari Mutua Terrassa. Universitat Autónoma de Barcelona, Gastroenterology, Terrassa, Spain; Young Group of GETECCU
